| Protocols | ||
|---|---|---|
| 4 protocol(s) meet the specified criteria | ||
| Drug: Atezolizumab | ||
| Protocol No. | Title | Status |
| GO29322 | A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered with Ipilimumab, Interferon-Alpha, or Other Immune-Modulating Therapies in Patients with Locally Advanced or Metastatic Solid Tumors | Open |
| GO29383 | A Phase Ib Study of the Safety and Pharmacology of Atezolizumab Administered with Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma or Atezolizumab Administered with Obinutuzumab or Tazemetostat in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Open |
| WO30070 | A Phase Iii, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of Atezolizumab (Anti−Pd-L1 Antibody) In Combination With Gemcitabine/Carboplatin Versus Gemcitabine/Carboplatin Alone In Patients With Untreated Locally Advanced Or Metastatic Urothelial Carcinoma Who Are Ineligible For Cisplatin-Based Therapy | Open |
| WO39210 | A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti−PD-L1 Antibody) As Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy | Open |